Krystal Biotech Inc (KRYS)
🔔 Watch stock
Appears in These Scanners
This stock currently matches 21 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Basics
Performance
Valuation
Profitability
Balance Sheet & Safety
Growth
Quality & Screener
AI Rating
Uses AIKrystal Biotech verkauft keine KI — das Kerngeschäft ist die zugelassene Gentherapie VYJUVEK gegen die Hautkrankheit Epidermolysis bullosa. Der Geschäftsbericht (10-K 2025) belegt jedoch operativen KI-Einsatz: Das Unternehmen hat nach eigener Angabe „in begrenzten Fällen" KI-Plattformen für konkrete geschäftliche Zwecke eingeführt und will KI nutzen, um die Entdeckung und Entwicklung neuer Produktkandidaten zu beschleunigen und die Fertigung zu optimieren. Damit ist KI ein internes Effizienz-Werkzeug (Kategorie „nutzt"), keine eigenständige Umsatzquelle (das schließt „verkauft" aus) und kein konkret gegen das eigene Geschäftsmodell gerichtetes Existenzrisiko (die AI-Risk-Factor-Passage bleibt allgemeine Boilerplate, das schließt „bedroht" aus).
View the full file — quotes, sources, reviewed filings
„As with many technological innovations, AI presents opportunities, risks and challenges that could impact our business... we have adopted and integrated in limited situations artificial intelligence platforms for limited specific business uses and may adopt and integrate additional AI platforms and/or tools into our business."
Wie bei vielen technologischen Innovationen bietet KI Chancen, Risiken und Herausforderungen, die unser Geschäft beeinflussen könnten... wir haben in begrenzten Fällen Plattformen der Künstlichen Intelligenz für begrenzte, konkrete geschäftliche Zwecke eingeführt und integriert und könnten weitere KI-Plattformen und/oder -Werkzeuge in unser Geschäft integrieren.
„Harnessing AI's potential may enable us to speed up the discovery and development of new product candidates, optimize our manufacturing processes, and drive efficiencies."
Das Potenzial der KI zu nutzen, könnte es uns ermöglichen, die Entdeckung und Entwicklung neuer Produktkandidaten zu beschleunigen, unsere Fertigungsprozesse zu optimieren und Effizienzen zu heben.
Rated on July 10, 2026 · How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 1.52 | 404.60 | 91 | 116.30 | 49.90 | 53 | 52 |
| 2025: Q1 | 1.20 | 3,659.60 | 88 | 94.90 | 40.50 | 31 | 25 |
| 2025: Q2 | 1.29 | 145.30 | 96 | 36.60 | 39.90 | 53 | 51 |
| 2025: Q3 | 2.66 | 192.70 | 98 | 16.60 | 81.20 | 40 | 38 |
| 2025: Q4 | 1.72 | 12.80 | 107 | 17.50 | 48.00 | 78 | 75 |
| 2026: Q1 | 1.83 | 53.30 | 116 | 31.90 | 48.10 | 80 | 73 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Krystal Biotech, Inc. ist ein Biotechnologieunternehmen in der kommerziellen Phase, das genetische Medikamente zur Behandlung von Erkrankungen mit hohem ungedecktem medizinischem Bedarf in den USA entdeckt, entwickelt, fertigt und kommerzialisiert.
| Employees | 295 |
|---|---|
| Headquarters | Pittsburgh, PA |
| Website | krystalbio.com |
| IPO Date | 20. Sep 2017 |
| Next Earnings | 3. Aug 2026 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Krish S. Krishnan M.B.A., M.S. | Founder, Chairman, President & CEO | 1965 |
| Suma M. Krishnan | Founder, President of R&D and Director | 1965 |
| Kathryn A. Romano CPA | Executive VP & Chief Accounting Officer | 1982 |
| John C. Thomas | EVP, General Counsel & Corporate Secretary | 1974 |
| John Karakkal | Vice President of North American Sales & Marketing | – |
| Stephane Paquette Ph.D. | Senior Vice President of Corporate Development | – |
| Josh Suskin | Senior Director & Head of US Human Resources | – |
| Laurent Goux | Executive VP & Head of International | 1975 |
| David Chien M.D. | Senior Vice President of Clinical Development | – |
| Christine Wilson | Senior VP & Head of US Commercial | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 20, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.